DE MARZO , Vincenzo

Before the percutaneous era, the mortality rate of patients with coronary heart disease not suitable for cardiac surgery was extremely high. This limit has been progressively exceeded with the advent of minimally invasive approaches, which, although initially intended exclusively for low risk scenarios, was then employed in complex patients...

Aims Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been evaluated in phase 3 randomized- controlled trials (RCTs) that enrolled individuals with heart failure and preserved ejection fraction (HFpEF) based on detailed clinical, biochemical, and echocardiographic criteria (hereafter HF-RCTs), and in cardiovascular outcomes trials...

Background: Following the availability of new drugs for chronic heart failure with reduced ejection fraction (HFrEF), we sought to provide an updated and comparative synthesis of the evidence on HFrEF pharmacotherapy efficacy. Methods: We performed a Bayesian network meta-analysis of phase 2 and 3 randomized controlled trials (RCTs) of medical...

AimsThis study aimed to determine whether any change occurred over time in level of evidence (LoE) of therapeutic interventions supporting heart failure (HF) and other European Society of Cardiology guideline recommendations. Methods and resultsWe selected topics with at least three documents released between 2008 and April 2022. Classes of...

To evaluate the safety and efficacy of the Orsiro sirolimus-eluting stent (Biotronik) in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (pPCI). Specific drug-eluting stent (DES) platforms might influence pPCI success rate in the mid-to-long term. Orsiro, a hybrid sirolimus DES with...

Aims: We assessed the efficacy of the drugs developed after neurohormonal inhibitors (NEUi) in patients with heart failure with reduced ejection fraction (HFrEF) and concomitant chronic kidney disease (CKD). Methods and results: The literature was systematically searched for phase 3 randomized controlled trials (RCTs) involving ≥90% patients...

No description

To provide an updated assessment of the efficacy-safety profile of very short (1 or 3 months) dual antiplatelet therapy (DAPT) compared to long (12 months) DAPT in patients undergoing percutaneous coronary interventions (PCI).

To compare safety and efficacy of very short (≤3 months), short (6 months), standard (12 months) and extended (>12 months) DAPT, and subsequent monotherapies, after DES.